Datapoint: United Therapeutics to Take On Pulmonary Hypertension With Tyvaso Approval Expansion

With a new FDA approval under its belt, United Therapeutics could have a blockbuster on its hands with the inhaled version of hypertension drug Tyvaso. The drug was approved last week for the treatment of pulmonary hypertension associated with interstitial lung disease. The original version of Tyvaso was approved to treat pulmonary arterial hypertension (PAH) in 2009. For the treatment of PAH, Tyvaso holds covered or better status for 84% of all insured lives under the pharmacy benefit. 5.7% of covered lives have preferred access to Tyvaso without utilization management restrictions.

SOURCE: MMIT Analytics, as of 5/25/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
March 27

Datapoint: Elevance to Acquire Kroger Specialty Pharmacy

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
March 26

Datapoint: Exchange Sign-Ups See 31% Annual Increase

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
March 25

Datapoint: Novo Working on New Weight Loss Pill

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today